Single comment threadYou are looking at one branch of the FLOW question that gets asked weekly, answered properly — 11 comments in the full submission. View in context.
-35
the FLOW question that gets asked weekly, answered properly
STEP. That is the whole post, but I will justify it. Everything else people worry about in c/orforglipron is downstream of it. Titration speed, early fullness, the endless dose arguments — most of it resolves if you sort STEP out first, and almost nobody does. I say this having got it wrong for 14 months. My eGFR was…
SURMOUNT-4 discontinuation arm showed regain. That is the reality of a chronic disease treatment, not a failure.
phase 2 is not phase 3, smaller n and shorter trial
You have restated the marketing copy. What is the actual substance here.
What was the dropout rate?
the discontinuation arms are the interesting part, not the STEP endpoints